Skip to content

Unveiling the Therapeutic Potential of Suyin Jiedu Formula in Diabetic Nephropathy: A Comprehensive Study Integrating Clinical Efficacy Network Pharmacology and Molecular Mechanisms

To explore the clinical study of Suyin Jiedu granule in the treatment of diabetic nephropathy based on FXR/NOX2 signal axis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000668
Enrollment
Unknown
Registered
2025-04-07
Start date
2025-01-15
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Control group:Losartan potassium was given orally 10 mg once daily
treatment group:The treatment group was orally administered Su Yin Jiedu Formula and losartan potassium (Su Yin Jiedu Formula was prepared by Yizhishan Hospital of Wannan Medical College 150 mL each t
losartan potassium 10 mg each time once a day)

Sponsors

Nanjing Pukou District Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age range: 18 - 80 years old; (2) Western medicine conforms to the WHO's criteria for type 2 diabetes; (3) It meets the Mogensen's early DN diagnostic criteria; (4) Traditional Chinese medicine conforms to the syndrome of Spleen and Kidney Qi Deficiency as stipulated in the relevant content of the "Clinical Research Guidelines for New Chinese Medicines" issued by the Ministry of Health.

Exclusion criteria

Exclusion criteria: (1) Patients with kidney diseases not caused by diabetes; (2) Those with serious diseases of important organs such as abnormal liver function renal failure heart failure stroke malignant tumors etc.; (3) Those with acute metabolic disorders such as diabetic ketoacidosis within the last 1 month; (4) Those with urinary tract infections menstruation intense exercise exposure to cold etc. under stress conditions; (5) Those with allergic constitutions; (6) patients with hyperlipidemia treated with statins;

Design outcomes

Primary

MeasureTime frame
mAlb;24-hour urinary protein quantification;TCM syndromes;Serum creatinine;

Secondary

MeasureTime frame
Blood lipids (triglycerides cholesterol low-density lipoprotein);Fasting blood glucose;2h postprandial blood glucose;Liver function (AST ALT);

Countries

China

Contacts

Public ContactHuang jiebo

Nanjing Pukou District Hospital of Traditional Chinese Medicine

drjiaj@163.com13814026290

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026